The development of immune checkpoint inhibitors (ICIs) has a tremendous effect on the
treatment options for multiple types of cancer. Nonetheless, there is a large interpatient …

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have been associated with
acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been …

Simple Summary Melanin biosynthesis can be a unique pathway to identify novel anti-
melanoma targeted molecules. In this approach, we specifically focused on the substrate of …

Background Sotorasib given after immunotherapy could put patients at increased risk of
hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation …

Introduction Checkpoint inhibitors (CPI) are widely used in cancer treatment with a potential
of causing immune-related adverse events (IRAEs). Several studies have reported a positive …

Background Immune checkpoint inhibitors (ICIs) have uncommon associations with
cardiotoxicity, yet these cardiotoxic effects are associated with high mortality. An accurate …

Abstract Objective Checkpoint inhibitors (CPIs) are in widespread clinical use. Little is
known about which patients are at risk for developing toxicity. It is essential being able to …

Simple Summary Currently, immune checkpoint inhibitors are the backbone of treatment for
multiple different types of advanced cancer in routine clinical practice. However, most …

Single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte–associated protein 4
(CTLA-4) gene, an inhibitor of T-cell priming, are associated with auto and alloimmunity …

Using data from 641 patients treated with anti-PD-1 or anti-PD-1 and anti-CTLA-4, the
authors examined how clinical characteristics related to grade 3 irAEs and none were found …